PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving Radiotherapy: From Theory to Clinical Practice.

Abstract Patients affected by glioblastoma often develop cerebral oedema as a life-threatening complication. Although there is no approved pharmacological intervention, such cerebral oedema is usually treated with dexamethasone. Dexamethasone has been shown in experimental studies to reduce cerebral oedema with only few mineralocorticoid side-effects. The goal of our study was to examine its efficacy in reducing the emergence of neurological deficits during the Stupp protocol.
PMID
Related Publications

The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma.

Therapeutic management of central nervous system lymphomas in a single hematological institute.

Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.

Corticosteroids compromise survival in glioblastoma.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Authors

Mayor MeshTerms
Keywords

Dexamethasone

GBM

QoL

brain tumour

neurological symptoms

oedema

Journal Title anticancer research
Publication Year Start




PMID- 29599372
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving
      Radiotherapy: From Theory to Clinical Practice.
PG  - 2423-2427
AB  - BACKGROUND: Patients affected by glioblastoma often develop cerebral oedema as a 
      life-threatening complication. Although there is no approved pharmacological
      intervention, such cerebral oedema is usually treated with dexamethasone.
      Dexamethasone has been shown in experimental studies to reduce cerebral oedema
      with only few mineralocorticoid side-effects. The goal of our study was to
      examine its efficacy in reducing the emergence of neurological deficits during
      the Stupp protocol. PATIENTS AND METHODS: We studied a retrospective cohort of
      459 patients, assigned in controlled groups: in group A, patients received
      radiochemotherapy followed by adjuvant chemotherapy; in group B, patients
      received an equivalent combined treatment with dexamethasone. RESULTS: The
      frequency of neurological symptoms was significantly lower in
      dexamethasone-treated patients. CONCLUSION: Early diagnosis and prevention of
      cerebral oedema are important because functional consequences can be anticipated 
      with an appropriate medical treatment. Thus, our study reveals that dexamethasone
      acts to prevent the appearance of neurological symptoms in patients with brain
      tumour.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Palombi, Lucia
AU  - Palombi L
AD  - Department of Neurological Sciences-Neurosurgery, Faculty of Medicine, La
      Sapienza University of Rome, Rome, Italy [email protected]
FAU - Marchetti, Paolo
AU  - Marchetti P
AD  - Department of Oncology, Faculty of Medicine and Psychology, La Sapienza
      University of Rome, Rome, Italy.
FAU - Salvati, Maurizio
AU  - Salvati M
AD  - IRCCS INM Neuromed, Pozzilli, Italy.
FAU - Osti, Mattia Falchetto
AU  - Osti MF
AD  - Department of Radiation Oncology, Faculty of Medicine and Psychology, La Sapienza
      University of Rome, Rome, Italy.
FAU - Frati, Luigi
AU  - Frati L
AD  - IRCCS INM Neuromed, Pozzilli, Italy.
FAU - Frati, Alessandro
AU  - Frati A
AD  - IRCCS INM Neuromed, Pozzilli, Italy.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Edema/etiology/*prevention & control
MH  - Brain Neoplasms/complications/pathology/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy/*methods
MH  - Cranial Irradiation/*adverse effects
MH  - Dexamethasone/administration & dosage
MH  - Female
MH  - Glioblastoma/complications/pathology/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - *Dexamethasone
OT  - *GBM
OT  - *QoL
OT  - *brain tumour
OT  - *neurological symptoms
OT  - *oedema
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/29 00:00 [received]
PHST- 2018/02/22 00:00 [revised]
PHST- 2018/02/27 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2423 [pii]
AID - 10.21873/anticanres.12494 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2423-2427. doi: 10.21873/anticanres.12494.